Alzheimer's Disease costs U.S. society over $100 billion annually, making it the 3rd most costly disease after heart disease and cancer.
Alzheimer's Disease affects 1 out of every 4 people over the age of 75, and 1 out of 3 people over 80.
Presently, there are 35 million cases of Alzheimer's Disease worldwide. This number is expected to increase to 115.4 million by 2050.
ADDF’s Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer’s Disease
The ADDF is very pleased that the FDA has approved Amyvid™, the first diagnostic test for Alzheimer’s disease. This approval marks an important milestone for early detection, diagnosis, treatment and patient care of Alzheimer’s disease and other cognitive disorders.
To view the full announcement, please click here.
Inaugural Hope on the Horizon Chicago Dinner – November 5, 2012
The ADDF will hold its Third Annual Fall Luncheon and Symposium – Hope on the Horizon: New Drugs for Alzheimer’s Disease – at the Metropolitan Club, New York City on Thursday, September 27, 2012.
This annual conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias.